文稿:傲雪
图片:网络
翻译:Darren
编辑:Jayden
10月31日卫生部消息，一种新的COVID-19药物可拯救生命并缩短住院时间。
新西兰卫生部长安德鲁-利特尔今天表示:新西兰已经获得了一种重要的COVID-19新药，可以拯救生命并缩短住院时间。
卫生部长说:”本月早些时候，我们是第一批购买莫努匹拉韦的国家之一，这种抗病毒药物在阻止COVID-19的轻度至中度症状的人需要去医院方面显示出良好的潜力。
今天，我非常高兴地看到药库已经获得了另一种重要的药物，可以帮助治疗中度至重度COVID-19患者，特别是那些免疫系统受损的患者。‘Ronapreve’是一种单克隆抗体药物，人们对它有很多兴奋点。临床显示它的作用是巨大的，因为它降低了COVID-19的严重程度，减少了患者将病毒传给其他人的风险。这一点非常重要，不仅因为它可以直接拯救生命，而且还因为它将为我们的医院减轻压力，这意味着他们可以继续治疗其他患者和有疾病的人。
国家药库药品采购机构已经获得了足够剂量的Ronapreve，能够治疗5300人，并期望明年能够购买更多。 当我们创建COVID-19特别预算时，我们期望能够迅速投入使用，为新西兰人能确保治疗，而行动。Ronapreve，连同莫努匹拉韦和其他药物，构成了我们对抗COVID-19大流行的武器库的一部分，以保护人们和医院服务免受其最严重的影响。
然而，其他行动仍然和以往一样重要。让至少90%的人接种疫苗，以及戴口罩和保持社交距离等实际措施，都是条件的一部分。
新西兰在应对COVID-19大流行病方面做得特别好。我们的感染率和死亡率只是其他国家的一小部分，因为我们已经做了需要做的事情，但我们仍需要继续努力”。注: Ronapreve（发音为row-na-preeve）正在接受医疗保险的评估，以批准在新西兰使用，但它已经在其他国家，包括英国获得批准。
31 October, New COVID-19 drug saves lives and cuts time in hospital
New Zealand has secured access to an important new COVID-19 drug that can save lives and cut time in hospital, Health Minister Andrew Little said today.
“Earlier this month, we were one of the first countries to buy molnupiravir, an anti-viral drug showing promising potential at stopping people with mild-to-medium symptoms of COVID-19 needing to go to hospital,” Andrew Little said.
“Today, I am very pleased that Pharmac has secured access to another important drug that could help treat people with medium-to-severe COVID-19, especially those with compromised immune systems.
“Ronapreve is a monoclonal antibody drug and there is a lot of excitement about it. The clinical advice is that it is a massive advance, because it reduces the severity of COVID-19 and decreases the risk of patients passing the virus on to other people.
“That’s hugely important, not only because of the lives it could save directly, but also because it will take pressure off our hospitals, which means they can get on with treating people with other conditions.
“Pharmac, the national drug-buying agency, has secured access to enough doses of Ronapreve to be able to treat 5300 people and expects to be able to buy more next year.
“When we created the special COVID-19 budget, we expected Pharmac to act quickly and secure treatments for New Zealand, and that’s what it’s doing.
“Ronapreve, along with molnupiravir and other drugs, form part of our armoury against the COVID-19 pandemic, protecting people and hospital services against its worst impacts.
“However, other actions are still just as important as they have ever been. Getting at least 90 per cent of people who can be vaccinated, and practical measures like wearing facemasks and social distancing are all part of the deal.
“New Zealand has done exceptionally well at dealing with the COVID-19 pandemic. Our infection and death rate is just a fraction of that in other countries because we’ve done what needed to be done, but we need to keep going.”
note: Ronapreve (pronounced row-na-preeve) is being assessed by Medsafe for approval for use in New Zealand, but it has been approved in other countries, including the United Kingdom.
备注和负责声明
未经书面许可，保留所有权利，不得使用任何部分或完整的文章或照片。本号转载的文章都已注明出处，如对版权有任何疑问，请在第一时间发送邮件给本号， bbcc1223@126.com我们将在收到后第一时间进行删除。
若喜欢作品的可以点击“在看”，这样有机会分享给更多朋友。要是再点击“喜欢作品”，那将对我们鼓舞更大。
本号致力于好文推送，并对文中观点保持中立，所发内容仅供学习、交流。版权归原作者或机构所有，部分文章推送时未能查实原作者，在这里对你们表示深深的敬意。若涉及版权问题，麻烦请留言联系删除